Download PDF
CC BY-NC-ND 4.0 · Rev Bras Ginecol Obstet 2018; 40(05): 242-250
DOI: 10.1055/s-0038-1655747
Original Article
Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Cost-effectiveness of Carbetocin versus Oxytocin for Prevention of Postpartum Hemorrhage Resulting from Uterine Atony in Women at high-risk for bleeding in Colombia

Rendimento da carbetocina versus oxitocina para a prevenção da hemorragia pós-parto resultante da atonia uterina em mulheres com alto risco de sangramento na Colômbia
Yaneth Gil-Rojas
1   NeuroEconomix, Bogota, Colombia
,
Pieralessandro Lasalvia
1   NeuroEconomix, Bogota, Colombia
,
Fabián Hernández
1   NeuroEconomix, Bogota, Colombia
,
Camilo Castañeda-Cardona
1   NeuroEconomix, Bogota, Colombia
,
Diego Rosselli
2   Department of Clinical Epidemiology and Biostatistics, Facultad de Medicina de la Pontificia Universidad Javeriana, Bogota, Colombia
› Author Affiliations
Further Information

Publication History

28 November 2017

04 April 2018

Publication Date:
18 June 2018 (online)

   Permissions and Reprints

Abstract

Objective To assess the cost-effectiveness of carbetocin versus oxytocin for prevention of postpartum hemorrhage (PPH) due to uterine atony after vaginal delivery/cesarean section in women with risk factors for bleeding.

Methods A decision tree was developed for vaginal delivery and another one for cesarean, in which a sequential analysis of the results was obtained with the use of carbetocin and oxytocin for prevention of PPH and related consequences. A third-party payer perspective was used; only direct medical costs were considered. Incremental costs and effectiveness in terms of quality-adjusted life years (QALYs) were evaluated for a one-year time horizon. The costs were expressed in 2016 Colombian pesos (1 USD = 3,051 Col$).

Results In the vaginal delivery model, the average cost of care for a patient receiving prophylaxis with uterotonic agents was Col$ 347,750 with carbetocin and Col$ 262,491 with oxytocin, while the QALYs were 0.9980 and 0.9979, respectively. The incremental cost-effectiveness ratio is above the cost-effectiveness threshold adopted by Colombia. In the model developed for cesarean section, the average cost of a patient receiving prophylaxis with uterotonics was Col$ 461,750 with carbetocin, and Col$ 481,866 with oxytocin, and the QALYs were 0.9959 and 0.9926, respectively. Carbetocin has lower cost and is more effective, with a saving of Col$ 94,887 per avoided hemorrhagic event.

Conclusion In case of elective cesarean delivery, carbetocin is a dominant alternative in the prevention of PPH compared with oxytocin; however, it presents higher costs than oxytocin, with similar effectiveness, in cases of vaginal delivery.

Resumo

Objetivo Avaliar a relação custo-eficácia da carbetocina versus oxitocina para prevenção de hemorragia pós-parto (HPP) vaginal e cesariana devido à atonia uterina em mulheres com fatores de risco para desenvolver sangramento.

Métodos Foram desenvolvidos protocolos de manejo para parto vaginal e outra para parto por cesárea e analisados resultados obtidos com carbetocina e oxitocina na prevenção de HPP, assim como, consequências relacionadas à ocorrência do evento hemorrágico. A perspectiva utilizada foi a do terceiro pagador, portanto, apenas os custos médicos diretos foram levados em consideração. Os custos incrementais e a eficácia em termos de anos de vida ajustados pela qualidade (QALY) foram avaliados para um horizonte de tempo de um ano. Os custos foram expressos em pesos colombianos de 2016 (1 USD = 3.051 Col$).

Resultados No modelo de parto vaginal, o custo médio de cuidados para um paciente que recebeu profilaxia com agentes uterotônicos foi de Col$ 347.750 com carbetocina e Col$ 262.491 com oxitocina, enquanto os QALYs foram 0,9980 e 0,9979, respectivamente. O índice incremental de custo-efetividade está acima do limite de custo-efetividade adotado pela Colômbia. No modelo desenvolvido para parto por cesárea, o custo médio do paciente que recebeu profilaxia com terapia uterotônica foi de Col$ 461.750 com carbetocina e Col$ 481.866 com oxitocina e os QALYs foram 0,9959 e 0,9926, respectivamente. A carbetocina foi a alternativa com menor custo e maior efetividade com uma economia de $94.887 por evento hemorrágico evitado.

Conclusão A carbetocina no parto eletivo por cesárea é uma alternativa dominante na prevenção da PPH em relação à oxitocina; porém representa custos mais altos com uma eficácia similar à da oxitocina no caso de parto vaginal.

Keywords

cost-effectiveness - carbetocin - oxytocin - prevention postpartum hemorrhage - pregnancy - high-risk

Palavras chave

análise custo-eficiência - carbetocina - oxitocina - prevenção - hemorragia pós-parto - gravidez de alto risco

Contributions

Gil-Rojas Y., Hernández F., Lasalvia P., Castañeda-Cardona C. and Rosselli D. contributed with the design, data collection, analysis and interpretation of the information, preparation of the preliminary publication, critical review and final approval of the version to be published.


 

  • References

  • 1 Organización Mundial de la Salud. Recomendaciones de la OMS para la Prevención y el Tratamiento de la Hemorragia Posparto. 2014. http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241548502/es/ . Accessed July 10, 2017
    PubMedGoogle Scholar
  • 2 Alkema L, Chou D, Hogan D. , et al; United Nations Maternal Mortality Estimation Inter-Agency Group collaborators and technical advisory group. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group. Lancet 2016; 387 (10017): 462-474 . Doi: 10.1016/S0140-6736(15)00838-7
    CrossrefPubMedGoogle Scholar
  • 3 de Salud M, Social P. Instituto Nacional de Salud. Sistema Nacional de Vigilancia en Salud Pública: Informes de Evento. 2016. http://www.ins.gov.co/lineas-de-accion/Subdireccion-Vigilancia/Paginas/informes-de-evento.aspx . Accessed July 11, 2017
    PubMedGoogle Scholar
  • 4 Ministerio de Salud y Protección Social - Colciencias. Guía de Práctica Clínica para la Prevención, Detección Temprana y Tratamiento del Embarazo, Parto o Puerperio . Guías N° 11–15. Bogotá: Minsalud; 2013. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/INEC/IETS/Gu%C3%ADa.completa.Embarazo.Parto.2013.pdf . Accessed July 10, 2017
    PubMedGoogle Scholar
  • 5 Mavrides E, Allard S, Chandraharan E. , et al. Prevention and management of postpartum haemorrhage. BJOG 2017; 124 (05) e106-e149 . Doi: 10.1111/1471-0528.14178
    CrossrefPubMedGoogle Scholar
  • 6 Leduc D, Senikas V, Lalonde AB. ; CLINICAL PRACTICE OBSTETRICS COMMITTEE. Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. J Obstet Gynaecol Can 2009; 31 (10) 980-993 . Doi: 10.1016/S1701-2163(16)34329-8
    CrossrefPubMedGoogle Scholar
  • 7 Instituto de Evaluación Tecnológica en Salud. Manual para la Elaboración de Evaluaciones Económicas en Salud . Bogotá: IETS; 2014
    Google Scholar
  • 8 Fescina R, De Mucio B, Ortiz E, Jarquin D. Guías para la Atención de las Principales Emergencias Obstétricas. 2012. http://www.clacaidigital.info:8080/xmlui/handle/123456789/782 . Accessed July 10, 2017
    PubMedGoogle Scholar
  • 9 Centro Nacional de Excelencia Tecnológica en Salud. Prevención y Manejo de la Hemorragia Obstetrica en el Primer, Segundo y Tercer Niveles de Atención . México: Secretaria de Salud; 2013. http://cenetec-difusion.com/gpc-sns/?p=1489 . Accessed July 10, 2017
    PubMedGoogle Scholar
  • 10 Del Angel García G, Garcia-Contreras F, Constantino-Casas P. , et al. Economic evaluation of carbetocin for the prevention of uterine atony in patients with risk factors in Mexico. Value Health 2006; 9: A254 . Doi: 10.1016/S1098-3015(10)63364-5
    CrossrefPubMedGoogle Scholar
  • 11 Rueda C, Caceres LA, Caicedo Navas AG. Costo-efectividad de carbetocina en comparación con oxitocina para prevenir hemorragia posparto por atonía uterina en pacientes con factores de riesgo en Colombia. Value Health 2013; 16: A709-A710 . Doi: 10.1016/j.jval.2013.08.2179
    CrossrefPubMedGoogle Scholar
  • 12 Kostyuk A, Akanov A, Almadiyeva A. Clinical effectiveness and cost-effectiveness of carbetocin for the prevention of postpartum hemorrhage. Value Health 2016; 19: A173 . Doi: 10.1016/j.jval.2016.03.1450
    CrossrefPubMedGoogle Scholar
  • 13 van der Nelson HA, Draycott T, Siassakos D, Yau CWH, Hatswell AJ. Carbetocin versus oxytocin for prevention of post-partum haemorrhage at caesarean section in the United Kingdom: An economic impact analysis. Eur J Obstet Gynecol Reprod Biol 2017; 210: 286-291 . Doi: 10.1016/j.ejogrb.2017.01.004
    CrossrefPubMedGoogle Scholar
  • 14 Moosivand A, Foroughi Moghadam M, Khedmati J, Mehralian G. Cost–utility analysis of carbetocin versus oxytocin for managing postpartum hemorrhage. Value Health 2016; 19: A177 . Doi: 10.1016/j.jval.2016.03.1440
    CrossrefPubMedGoogle Scholar
  • 15 Ministerio de Salud y Protección Social. Regulación de Precios de Medicamentos: Listado de Medicamentos con Precio Regulado . Bogotá: Minsalud; 2017. https://www.minsalud.gov.co/salud/MT/Paginas/medicamentos-regulacion-precios.aspx . Accessed November 15, 2017
    PubMedGoogle Scholar
  • 16 de Salud M. . Instituto de Seguros Sociales. Acuerdo 256 de 2001. Manual de Tarifas de la Entidad Promotora de Salud EPS-ISS. 2001. https://lexsaludcolombia.files.wordpress.com/2010/10/tarifas-iss-2001.pdf . Accessed July 10, 2017
    PubMedGoogle Scholar
  • 17 Departamento Nacional de Planeación. Colombia Compra Eficiente. SECOP I. 2017. https://www.colombiacompra.gov.co/compradores/secop-i . Accessed July 12, 2017
    PubMedGoogle Scholar
  • 18 Ministerio de Salud y Protección Social. Sistema de Información de Prestaciones de Salud. 2017. http://www.sispro.gov.co/recursosapp/ruaf/pages/rips.aspx . Accessed July 11, 2017
    PubMedGoogle Scholar
  • 19 Departamento Administrativo Nacional de Estadísticas (DANE). Estadísticas Vitales de Colombia. 2014. http://www.dane.gov.co/index.php/poblacion-y-demografia/nacimientos-y-defunciones/118-demograficas/estadisticas-vitales/2877-defunciones-no-fetales . Accessed July 11, 2017
    PubMedGoogle Scholar
  • 20 Sheldon WR, Blum J, Vogel JP, Souza JP, Gülmezoglu AM, Winikoff B. ; WHO Multicountry Survey on Maternal and Newborn Health Research Network. Postpartum haemorrhage management, risks, and maternal outcomes: findings from the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG 2014; 121 (Suppl. 01) 5-13 . Doi: 10.1111/1471-0528.12636
    Google Scholar
  • 21 Boucher M, Nimrod CA, Tawagi GF, Meeker TA, Rennicks White RE, Varin J. Comparison of carbetocin and oxytocin for the prevention of postpartum hemorrhage following vaginal delivery:a double-blind randomized trial. J Obstet Gynaecol Can 2004; 26 (05) 481-488 . Doi: 10.1016/S1701-2163(16)30659-4
    CrossrefPubMedGoogle Scholar
  • 22 Borruto F, Treisser A, Comparetto C. Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trial. Arch Gynecol Obstet 2009; 280 (05) 707-712 . Doi: 10.1007/s00404-009-0973-8
    CrossrefPubMedGoogle Scholar
  • 23 Attilakos G, Psaroudakis D, Ash J. , et al. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG 2010; 117 (08) 929-936 . Doi: 10.1111/j.1471-0528.2010.02585.x
    CrossrefPubMedGoogle Scholar
  • 24 Plunkett BA, Grobman WA. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol 2005; 192 (04) 1153-1161 . Doi: 10.1016/j.ajog.2004.10.600
    CrossrefPubMedGoogle Scholar
  • 25 Fawsitt CG, Bourke J, Greene RA, Everard CM, Murphy A, Lutomski JE. At what price? A cost-effectiveness analysis comparing trial of labour after previous caesarean versus elective repeat caesarean delivery. PLoS One 2013; 8 (03) e58577 . Doi: 10.1371/journal.pone.0058577
    CrossrefPubMedGoogle Scholar
  • 26 Dansereau J, Joshi AK, Helewa ME. , et al. Double-blind comparison of carbetocin versus oxytocin in prevention of uterine atony after cesarean section. Am J Obstet Gynecol 1999; 180 (3 Pt 1): 670-676 . Doi: 10.1016/S0002-9378(99)70271-1
    CrossrefPubMedGoogle Scholar
  • 27 Elbohoty AE, Mohammed WE, Sweed M, Bahaa Eldin AM, Nabhan A, Abd-El-Maeboud KH. Randomized controlled trial comparing carbetocin, misoprostol, and oxytocin for the prevention of postpartum hemorrhage following an elective cesarean delivery. Int J Gynaecol Obstet 2016; 134 (03) 324-328 . Doi: 10.1016/j.ijgo.2016.01.025
    CrossrefPubMedGoogle Scholar
  • 28 Holleboom CA, van Eyck J, Koenen SV. , et al. Carbetocin in comparison with oxytocin in several dosing regimens for the prevention of uterine atony after elective caesarean section in the Netherlands. Arch Gynecol Obstet 2013; 287 (06) 1111-1117 . Doi: 10.1007/s00404-012-2693-8
    CrossrefPubMedGoogle Scholar
  • 29 Taheripanah R, Shoman A, Karimzadeh MA, Zamaniyan M, Malih N. Efficacy of oxytocin versus carbetocin in prevention of postpartum hemorrhage after cesarean section under general anesthesia: a prospective randomized clinical trial. J Matern Fetal Neonatal Med 2017; 25: 1-6 . Doi: 10.1080/14767058.2017.1355907
    PubMedGoogle Scholar